Archivio

The ZIKAction Kick-Off Meeting was a success!

Kaposi Sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from Eastern Africa, Southern Africa, Europe and Asia.

PENTA Foundation coordinated ZIKAction consortium

First patient enrolled in ODYSSEY study

First patient enrolled in PED-MERMAIDS study

Editorial Overview: Virus–vector interactions

Is pregnancy a barrier to the proposed lower dose of efavirenz?

Timing of the postpartum curve in pharmacokinetic studies in pregnancy should not be too early

A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

The 1st patient was screened in SMILE in Spain

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women

High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

First reported use of elvitegravir and cobicistat during pregnancy